# CHD2

Source: https://onco.cc/targets/chd2/  
OnCo record `chd2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CHD2 (ATP-dependent chromatin remodeler CHD2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Bladder & urothelial cancer and 5 more.

## Summary

ATP-dependent chromatin-remodeling factor that specifically binds to the promoter of target genes, leading to chromatin remodeling, possibly by promoting deposition of histone H3.3. Involved in myogenesis via interaction with MYOD1: binds to myogenic gene regulatory sequences and mediates incorporation of histone H3.3 prior to the onset of myogenic gene expression, promoting their expression.

IntOGen calls it a driver in 7 cohorts (3 activating, 4 loss-of-function), covering Bladder Urothelial Carcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Gastrointestinal Stromal Tumour, Papillary Renal Cell Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: chromodomain helicase DNA binding protein 2; ATP-dependent chromatin remodeler CHD2; FLJ38614; DKFZp547I1315; DKFZp781D1727; DKFZp686E01200
- Tags: cancer-genes-wave
- Symbol: CHD2
- Class: transcription
- Biology: ATP-dependent chromatin-remodeling factor that specifically binds to the promoter of target genes, leading to chromatin remodeling, possibly by promoting deposition of histone H3.3. Involved in myogenesis via interaction with MYOD1: binds to myogenic gene regulatory sequences and mediates incorporation of histone H3.3 prior to the onset of myogenic gene expression, promoting their expression. Location: Nucleus (UniProt). Locus 15q26.1 (HGNC).
- Where found: Leukaemia: Open Targets association 0.74 with leukaemia (MONDO_0005059); Non-Hodgkin lymphoma: Open Targets association 0.72 with non-Hodgkin lymphoma (MONDO_0018908); Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA); Renal cell carcinoma: IntOGen driver in 1 cohort (PRCC); Acute lymphoblastic leukaemia: Open Targets association 0.72 with acute lymphoblastic leukaemia (MONDO_0004967); Chronic lymphocytic leukaemia: Open Targets association 0.71 with B-cell chronic lymphocytic leukaemia (MONDO_0004948); IntOGen driver in 4 cohorts (CLLSLL)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:1917: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1917
- UniProt O14647: https://www.uniprot.org/uniprotkb/O14647/entry
- NCBI Gene 1106: https://www.ncbi.nlm.nih.gov/gene/1106
- Ensembl ENSG00000173575: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173575

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Gastrointestinal stromal tumour (GIST)](https://onco.cc/cancers/gist/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Papillary renal cell carcinoma](https://onco.cc/cancers/papillary-rcc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)

---
JSON: https://onco.cc/api/v1/entities/chd2.json